



**Chemistree Technology Inc.**

**Consolidated Financial Statements**

**For the years ended June 30, 2021 and 2020**

## INDEPENDENT AUDITOR'S REPORT

To the Shareholders of  
Chemistree Technology Inc.

### *Opinion*

We have audited the accompanying consolidated financial statements of Chemistree Technology Inc. (the "Company"), which comprise the consolidated statements of financial position as at June 30, 2021 and 2020 and the consolidated statements of loss and comprehensive loss, cash flows, and changes in shareholders' equity (deficiency) for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at June 30, 2021 and 2020, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards ("IFRS").

### *Basis for Opinion*

We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our opinion.

### *Material Uncertainty Related to Going Concern*

We draw attention to Note 1 of the consolidated financial statements, which indicates that the Company had a working capital deficit of \$6,342,110 and an accumulated deficit of \$26,233,624. As stated in Note 1, these events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

### *Other Information*

Management is responsible for the other information. The other information obtained at the date of this auditor's report includes Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.



We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### ***Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

### ***Auditor's Responsibilities for the Audit of the Consolidated Financial Statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Erez Bahar.

A handwritten signature in black ink that reads "Davidson & Company LLP". The signature is written in a cursive, flowing style.

Vancouver, Canada

Chartered Professional Accountants

October 5, 2021

# Chemistree Technology Inc.

(in Canadian Dollars)

## Consolidated Statements of Financial Position

As at June 30,	2021	2020
<b>ASSETS</b>		
<b>Current</b>		
Cash and cash equivalents	\$ 395,682	\$ 3,247,533
Receivables (Note 17)	71,391	165,983
Taxes receivable	32,898	71,716
Prepays and deposits	32,110	34,281
Net investment in sublease (Note 12)	148,462	142,481
Assets held for sale (Note 4)	1,620,323	-
	<b>2,300,866</b>	<b>3,661,994</b>
<b>Non-current assets</b>		
Investment (Note 16)	500,000	280,257
Property and equipment (Note 4)	942,569	2,830,948
Note receivable (Note 14)	-	523,415
Net investment in sublease (Note 12)	-	156,729
	<b>\$ 3,743,435</b>	<b>\$ 7,453,343</b>
<b>LIABILITIES</b>		
<b>Current</b>		
Accounts payable and accrued liabilities	\$ 65,391	\$ 139,134
Due to related parties (Note 6)	-	695
Lease liability (Note 12)	141,339	154,094
Interest payable (Note 5)	65,537	52,377
Convertible debentures (Note 8)	8,370,709	-
	<b>8,642,976</b>	<b>346,300</b>
Convertible debentures (Note 8)	-	7,739,770
Liabilities held for sale (Note 4)	65,665	-
Lease liability (Note 12)	-	141,273
Notes payable (Note 5)	443,959	443,959
	<b>9,152,600</b>	<b>8,671,302</b>
<b>SHAREHOLDERS' DEFICIENCY</b>		
Share capital (Note 7)	17,603,443	17,207,845
Equity reserves (Notes 7)	3,221,016	3,273,842
Deficit	(26,233,624)	(21,699,646)
	<b>(5,409,165)</b>	<b>(1,217,959)</b>
	<b>\$ 3,743,435</b>	<b>\$ 7,453,343</b>

Nature and continuance of operations (Note 1)

Commitments (Note 15)

Covid-19 pandemic (Note 18)

Events after the reporting period (Note 20)

Approved by the board on October 5, 2021:

Signed: "Karl Kottmeier"  
Director

Signed: "Douglas Ford"  
Director

# Chemistree Technology Inc.

(in Canadian Dollars)

## Consolidated Statements of Loss and Comprehensive Loss

For the years ended June 30,	2021	2020
<b>Revenue</b> (Note 3)	\$ -	\$ 161,050
Cost of sales	-	(120,000)
<b>Gross margin</b>	\$ -	\$ 41,050
<b>Expenses</b>		
Accretion and finance costs (Note 8)	1,874,998	1,726,366
Accretion and leases (Note 12)	22,017	37,242
Bad debt expense (Note 17)	199,231	689,125
Depreciation (Note 4)	105,413	124,243
Consulting	24,683	272,037
General and administrative (Note 6)	297,985	719,229
Impairment (Note 12, 14,16)	943,197	685,429
Insurance	5,194	11,797
Interest expense	13,160	18,173
Management fees (Note 6)	961,643	1,104,292
Professional fees	113,574	168,225
Share-based payments (Note 7)	-	58,000
Transfer agent and regulatory fees	63,839	75,243
Travel	-	45,868
<b>Total expenses</b>	<b>(4,624,934)</b>	<b>(5,735,269)</b>
Foreign exchange gain (loss)	(99,534)	123,392
Interest income	45,026	174,797
Gain (loss) on sale of Marketable Securities	1,042	(101,983)
Gain on sublease (Note 12)	102,598	4,913
Other income	41,824	39,648
<b>Loss and comprehensive loss</b>	<b>\$ (4,533,978)</b>	<b>\$ (5,453,452)</b>
<b>Basic and diluted loss per share</b>	<b>\$ (0.12)</b>	<b>\$ (0.14)</b>
<b>Weighted average number of shares outstanding - basic and diluted</b>	<b>38,440,868</b>	<b>37,641,534</b>

# Chemistree Technology Inc.

(in Canadian Dollars)

## Consolidated Statements of Cash Flows

For the years ended June 30,	2021	2020
<b>OPERATING ACTIVITIES</b>		
Loss for the year	\$ (4,533,978)	\$ (5,453,452)
Items not affecting cash:		
Depreciation	105,413	124,243
Accrual of interest receivable	(45,026)	(84,010)
Accrual of interest payable	13,160	18,172
Bad debt expense	199,231	689,125
Impairment	943,197	685,429
Share-based payments	-	58,000
Accretion of convertible debentures	937,711	766,197
Accretion of lease (net)	(19,807)	2,015
Loss (gain) on sale of marketable securities	-	101,983
Foreign exchange	68,705	168
Gain on sub-lease	(102,598)	(4,647)
Changes in non-cash working capital items:		
Receivables and prepaids	57,886	(120,943)
Accounts payable and accrued liabilities, and due to related parties	(74,438)	24,224
<b>Cash used in operating activities</b>	<b>(2,450,544)</b>	<b>(3,193,496)</b>
<b>INVESTING ACTIVITIES</b>		
Property and equipment purchases	(58,679)	(171,203)
Investment	(500,000)	(280,257)
Proceeds from deposit on Property	65,665	-
Proceeds from sale of Marketable Securities	-	72,067
Note receivable	-	(464,715)
<b>Cash used in investing activities</b>	<b>(493,014)</b>	<b>(844,108)</b>
<b>FINANCING ACTIVITIES</b>		
Common shares issued for cash	36,000	-
Lease payments made	(154,293)	(162,414)
Lease payments received	210,000	161,035
<b>Cash provided by (used in) financing activities</b>	<b>91,707</b>	<b>(1,379)</b>
<b>Change in cash and cash equivalents during the year</b>	<b>(2,851,851)</b>	<b>(4,038,983)</b>
<b>Cash and cash equivalents, beginning of year</b>	<b>3,247,533</b>	<b>7,286,516</b>
<b>Cash and cash equivalents, end of year</b>	<b>\$ 395,682</b>	<b>\$ 3,247,533</b>
<b>Cash paid for:</b>		
Interest	\$ 937,286	\$ 960,168
Income taxes	\$ -	\$ -
<b>Cash and cash equivalents comprises:</b>	<b>2021</b>	<b>2020</b>
Cash	\$ 395,682	\$ 3,247,533
Cash equivalents	-	-
	<b>\$ 395,682</b>	<b>\$ 3,247,533</b>

Supplemental disclosure with respect to cash flows (Note 11)

# Chemistree Technology Inc.

(in Canadian Dollars)

## Consolidated Statements of Changes in Shareholders' Equity (Deficiency) For the years ended June 30,

	Number of shares	Share capital	Equity reserves	Deficit	Total
Balance, June 30, 2019	37,384,430	\$ 17,075,475	\$ 3,225,330	\$ (16,246,194)	\$ 4,054,611
Shares issued upon debenture conversions	330,000	132,370	(9,488)	-	122,882
Share-based payments - options	-	-	58,000	-	58,000
Loss for the year	-	-	-	(5,453,452)	(5,453,452)
<b>Balance, June 30, 2020</b>	<b>37,714,430</b>	<b>\$ 17,207,845</b>	<b>\$ 3,273,842</b>	<b>\$ (21,699,646)</b>	<b>\$ (1,217,959)</b>
Shares issued upon option exercises	600,000	60,000	(24,000)	-	36,000
Shares issued upon debenture conversions	720,000	335,598	(28,826)	-	306,772
Loss for the year	-	-	-	(4,533,978)	(4,533,978)
<b>Balance, June 30, 2021</b>	<b>39,034,430</b>	<b>\$ 17,603,443</b>	<b>\$ 3,221,016</b>	<b>\$ (26,233,624)</b>	<b>\$ (5,409,165)</b>



---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

### 1. NATURE AND CONTINUANCE OF OPERATIONS

Chemistree Technology Inc. (the “Company”) was incorporated in the Province of British Columbia on March 14, 2008, under the Business Corporations Act of British Columbia. The name change to Chemistree Technology Inc. became effective August 3, 2017. The Company’s head office is located at Suite 204 - 998 Harbourside Drive, North Vancouver, British Columbia.

The Company is a Canadian investment company with holdings in the U.S. cannabis sector, real estate, and a consumer-targeted biotechnology venture. The Company operates through its wholly-owned subsidiaries American CHM Investments Inc., CHM Desert LLC and Chemistree Washington Ltd. (Note 2). The Company’s corporate strategy is to focus on opportunistic investments across a broad range of industries, and is seeking to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s management expertise.

On October 30, 2020, the Company completed a previously announced internal review of its investment policy. Chemistree’s board of directors amended the Company’s investment policy (the “Investment Policy”) to broaden the investment mandate to include potential opportunities in the cannabis sector plus additional opportunities unrelated to the cannabis sector. Prior to broadening the mandate, the Company’s investment objectives were to seek opportunities in the cannabis sector, initially in the U.S. Pacific Northwest and California and potentially other jurisdictions where cannabis-related activities are permitted, and to achieve an acceptable rate of return by focusing on opportunities with attractive risk to reward profiles. In order to deploy the remaining investment capital with a more diversified approach, the amended Investment Policy includes, but is not limited to, other opportunities in the cannabis, health care, technology, biotechnology, medical technology or related consumer products fields. Investments by the Company are to be made in accordance with and are otherwise subject to the Investment Policy, which may be amended from time to time at the sole discretion of the Company without shareholder approval, unless required by applicable laws or CSE policies.

The ability of the Company to continue to operate as a going concern is dependent on its ability to generate profitable operations and positive cash flows. To date, the Company has generated limited revenues from operations and will require additional funds to meet ongoing obligations and investment objectives. Most significant in the near term are the convertible debentures, which come due on March 29, 2022. The Company does not have sufficient working capital to repay these debentures if they are not converted, and management and the Board of Directors are evaluating potential options for restructuring the terms of the debentures with the debenture holders. There are no guarantees that such an agreement will be achieved.

As at June 30, 2021, the Company had a working capital deficit of \$6,342,110 (2020: surplus of \$3,315,694) and an accumulated deficit of \$26,233,624 (2020: \$21,699,646). These consolidated financial statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company’s future capital requirements will depend on many factors, including the operating and capital costs of locating, researching, developing, and acquiring investments that comply with its investment strategy. The Company’s anticipated operating losses and increasing working capital requirements will require that it obtain additional capital to continue operations. The Company will depend almost exclusively on outside capital. Such outside capital may include the sale of additional shares. There can be no assurance that capital will be available as necessary to meet ongoing obligations and operating objectives or, if the capital is available, that it will be on terms acceptable to the Company. These conditions and uncertainties may cast significant doubt as to the Company’s ability to continue as a going concern. The issuances of additional equity securities by the Company may result in significant dilution to the equity

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

---

interests of its current shareholders. Obtaining commercial loans, assuming those loans would be available, would increase the Company's liabilities and future cash commitments.

## 2. BASIS OF PREPARATION

### Statement of Compliance

These consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

### Basis of Measurement

These consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified as fair value through profit or loss, which are stated at their fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information. These consolidated financial statements are presented in Canadian dollars, unless otherwise noted, which is the functional currency of the Company.

### Principles of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries, with intercompany balances and transactions eliminated on consolidation. Subsidiaries are those entities over which the Company has control, which exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and is exposed to the variable returns from its activities. As of June 30, 2021, subsidiaries over which the Company has control are listed below.

American CHM Investments Inc.	100%	Investment holding company
CHM Desert LLC	100% (indirect)	Investment holding company
Chemistree Washington Ltd.	100% (indirect)	Investment holding company

Chemistree Washington Ltd. ("Chemistree Washington"), was incorporated by the Company on October 17, 2017, to facilitate the Company's investment objectives in the Washington State cannabis sector. Effective July 17, 2018, the Company incorporated American CHM Investments Inc. ("American CHM"), under the laws of the State of Delaware. Effective July 18, 2018, American CHM incorporated CHM Desert LLC ("CHM Desert") as a wholly-owned subsidiary, under the laws of the State of California.

## 3. SIGNIFICANT ACCOUNTING POLICIES

### Cash and cash equivalents

The Company considers all highly liquid instruments, generally with a maturity of three months or less at the time of issuance, to be cash equivalents.

### Critical accounting estimates and judgments

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual experience may differ from these estimates and assumptions.

The effect of a change in an accounting estimate is recognized prospectively by including it in profit or loss in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both.

---

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

---

Information about critical accounting estimates and judgments in applying accounting policies that have the most significant risk of causing a material adjustment to the carrying amounts of assets and liabilities recognized in the consolidated financial statements are discussed below:

*Judgments:*

The preparation of these consolidated financial statements requires management to make judgments regarding the going concern of the Company, as discussed in Note 1.

*Collectability of receivables*

In order for management to determine expected credit losses in accordance with IFRS 9, we are required to make estimates based on historical information related to collections, in addition to taking the current condition of our customers credit quality into account.

*Estimates:*

*Impairment and useful lives of long-lived assets*

The Company assesses long-lived assets for possible impairment if there are events or changes in circumstances that indicate that carrying values of the assets may not be recoverable, or at least annually. The assessment of any impairment is dependent upon estimates of recoverable amounts that take into account factors such as location and condition of the asset, economic and market conditions, the useful lives of assets, and their related salvage values. The estimated useful lives of equipment are reviewed by management and adjusted if necessary. To estimate equipment's useful life, management must use its past experience with the same or similar assets, and review industry practices for similar pieces of equipment.

*Valuation of investments*

The Company recognizes and carries its investments at fair value. Fair value is determined on the basis of market prices from independent sources, if available. If there is no market price, then the fair value is determined by using valuation models with inputs derived from observable market data where possible, but where observable data is not available, judgment is required to establish fair values. There is inherent uncertainty and imprecision in estimating the factors that can affect fair value, and in estimating fair values generally, when observable data is not available. Changes in assumptions and inputs used in valuing financial instruments could affect reported fair values.

*Deferred income taxes*

In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized. At the end of each reporting period, the Company reassesses unrecognized income tax assets.

Basic and diluted loss per share

The Company presents basic loss per share for its common shares, calculated by dividing the loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share does not adjust the loss attributable to common shareholders or the weighted average number of common shares outstanding when the effect is anti-dilutive.

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

### Financial instruments

#### Financial assets:

Financial assets are classified at initial recognition as either: amortized cost, fair value through profit or loss ("FVTPL"), or fair value through other comprehensive income ("FVTOCI"). The classification depends on the Company's business model for managing the financial assets and the contractual cash flow characteristics. For assets measured at fair value, gains and losses will either be recorded in profit or loss or other comprehensive income.

*Fair value through profit or loss* – Financial assets carried at FVTPL are initially recorded at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial asset held at FVTPL are included in profit or loss in the period in which they arise.

*Fair value through other comprehensive income ("FVTOCI")* - Investments in equity instruments at FVTOCI are initially recognized at fair value plus transaction costs. Subsequently, they are measured at fair value, with gains and losses arising from changes in fair value recognized in other comprehensive income. There is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment.

*Financial assets at amortized cost* - A financial asset is measured at amortized cost if the objective of the business model is to hold the financial asset for the collection of contractual cash flows, and the asset's contractual cash flows are comprised solely of payments of principal and interest. They are classified as current assets or non-current assets based on their maturity date and are initially recognized at fair value and subsequently carried at amortized cost less any impairment.

#### Financial liabilities:

The Company classifies its financial liabilities into one of two categories, depending on the purpose for which the liability was acquired. The Company's accounting policy for each category is as follows:

*Fair value through profit or loss* – This category comprises derivatives, or liabilities acquired or incurred principally for the purpose of selling or repurchasing it in the near term. They are carried in the statements of financial position at fair value with changes in fair value recognized in profit or loss.

*Other financial liabilities:* This category consists of liabilities carried at amortized cost using the effective interest rate method.

The Company has classified its cash and cash equivalents and investment as fair value through profit and loss. Receivables and note receivable are classified as amortized cost. The Company's accounts payable and accrued liabilities, due to related parties, interest payable, convertible debentures, and notes payable are classified as other financial liabilities.

### Revenue Recognition

The Company recognizes revenue when it is earned and realizable based on the following criteria: persuasive evidence of an arrangement exists, services have been rendered, the price is fixed and determinable, and collectability is reasonably assured.

The Company applies the standards under IFRS 15, "Revenue from Contracts with a Customer". Revenues are recognized on a gross basis, when a service has been delivered, with the cost of obtaining the service being presented as cost of sales. When evaluating presentation of revenue, the Company looks at whether the transaction represents a principal or agency relationship. A party is considered a principal if:

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

- The entity has the primary responsibility for providing the services to the customer,
- The entity has latitude in establishing prices, either directly or indirectly,
- The entity bears the customer's credit risk on the receivable due from the customer.

The Company obtained revenue from providing consulting services at \$US 10,000 per month to the Washington Strategic Partner (Note 4). Due to a prolonged period of collection uncertainty, the Company determined that these arrangements no longer met revenue recognition criteria in the year ended June 30, 2021.

### Property and Equipment

Property and Equipment is stated at cost less accumulated depreciation and accumulated impairment losses. The cost of an item consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located.

Depreciation is provided at rates calculated to amortize the cost of the item, less its estimated residual value, using the diminishing balance method over its expected period of use by the Company. Estimated useful lives are reviewed by management and adjusted if necessary. Depreciation does not apply to real property. The Company's equipment is depreciated at a rate of 10%.

Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to profit or loss during the period they are incurred.

### Leases

The Company, on adoption of IFRS 16, recognized a lease liability and an investment in a sublease in relation to its commercial lease. In relation, this lease is measured as the lease liability at the present value of the remaining lease payments, discounted using the Company's incremental borrowing rate of 10% as at July 1, 2019.

#### *Right-of-use-assets:*

The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over a time period based on the shorter of their estimated useful life and the lease term. Right-of-use assets are subject to impairment.

#### *Lease liabilities:*

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the

---

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

---

commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

*Short-term leases and leases of low-value assets:*

The Company applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered of low value. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.

*Sub-leases:*

When the Company subleases a right-of-use asset, the Company classifies the sublease as an operating lease if the head lease is a short-term lease. Otherwise, the sublease is classified as a finance lease. When the sublease is classified as a finance lease, the lessor derecognizes the right-of-use asset pertaining to the head lease that it transfers to the sublessee, at the commencement date, but continues to account for the original lease liability. The sublessor recognizes a net investment in sublease and evaluates it for impairment and may use the discount rate in the head lease to measure the net investment in sublease. The Company recognizes finance income on the net investment in sublease, and also records income relating to variable lease payments not included in the measurement of the net investment in the lease.

Share Capital

Proceeds from the exercise of stock options and warrants are recorded as share capital in the amount for which the option or warrant enabled the holder to purchase a share in the Company, in addition to the proportionate amount of equity reserves originally created at the issuance of the stock options or warrants. Share capital issued for non-monetary consideration is valued at the closing market price at the date of issuance. The proceeds from the issuance of units are allocated between common shares and common share purchase warrants based on the residual value method. Under this method, the proceeds are allocated to common shares based on the fair value of a common share at the issuance date of the unit offering and any residual remaining is allocated to common share purchase warrants. All professional fees and commissions incurred directly with the issue of the Company's shares are charged directly to share capital as share issue costs. Warrants issued to agents in connection with a financing are recorded at fair value and charged to share capital as a share issue cost an offsetting entry to equity reserves within shareholders' equity.

Foreign exchange

The functional and reporting currency of the Company and its subsidiaries is the Canadian dollar. The functional currency determinations were conducted through an analysis of the consideration factors identified in IAS 21, *The Effects of Changes in Foreign Exchange Rates*.

Transactions denominated in other currencies are translated into their Canadian dollar equivalents at exchange rates prevailing at the transaction date. Carrying values of monetary assets and liabilities denominated in foreign currencies are adjusted at the statement of financial position date to reflect exchange rates prevailing at that date. Non-monetary assets and liabilities are translated at historical exchange rates. Gains and losses on translation are included in determining profit or loss for the year.

Income taxes

Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year end, adjusted for amendments to tax payable with regards to previous years.

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

Deferred tax is recorded by providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities that affect neither accounting or taxable loss; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the statement of financial position date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

### Impairment of non-financial assets

At each financial position reporting date the carrying amounts of the Company's long-lived assets are reviewed to determine whether there is any indication that those assets are impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use, which is the present value of future cash flows expected to be derived from the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in the profit or loss for the year.

For the purposes of impairment testing, individual assets are allocated to cash-generating units. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

### Share-based payments

The fair value of stock options granted is recognized as share-based payment expense with a corresponding increase in equity reserves. An individual is classified as an employee when the individual is an employee for legal or tax purposes (direct employee) or provides services similar to those performed by a direct employee.

Fair value is measured at grant date, and each tranche is recognized using the graded vesting method over the period during which the options vest. The fair value of the options granted is measured using the Black-Scholes option pricing model, taking into account the terms and conditions upon which the options were granted. At each financial position reporting date, the amount recognized as an expense is adjusted to reflect the actual number of stock options that are expected to vest. In situations where equity instruments are issued to consultants and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at the fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of goods or services received.

### Provisions

The Company recognizes liabilities for statutory, contractual, constructive or legal obligations associated with the retirement or reclamation of equipment. The net present value of cost estimates is capitalized to the related assets along with a corresponding increase in the provision in the year incurred. Discount rates using a pre-tax rate that reflect the time value of money are used to calculate the net present value.

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

The Company's estimates of provisions could change as a result of changes in regulatory requirements, discount rates and assumptions regarding the amount and timing of the future expenditures. These changes are recorded directly to the related assets with a corresponding entry to the provision. The Company's estimates are reviewed annually for changes in regulatory requirements, discount rates, effects of inflation and changes in estimates. Changes in the net present value, excluding changes in the Company's estimates of reclamation costs, are charged to profit and loss for the year.

### Assets held for sale

Non-current assets held for sale and disposal groups are presented separately in the current section of the statement of financial position when management is committed to immediately sell the asset or disposal group in its present condition, and this distribution is highly probable and expected to be completed within one year. Immediately before the initial classification of the asset and disposal groups as held for sale, the carrying amounts of the assets, or all the assets and liabilities in the disposal groups, are measured at the lower of their carrying amount and fair value less costs to sell.

### New Accounting Standards

Certain accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are either not applicable or are not expected to have a significant impact on the Company's financial statements.

#### IAS 16 - "Property, Plant and Equipment"

The IASB issued an amendment to IAS 16, Property, Plant and Equipment to prohibit the deducting from property, plant and equipment amounts received from selling items produced while preparing an asset for its intended use. Instead, sales proceeds and its related costs must be recognized in profit or loss. The amendment will require companies to distinguish between costs associated with producing and selling items before the item of property, plant and equipment is available for use and costs associated with making the item of property, plant and equipment available for its intended use. The amendment is effective for annual periods beginning on or after January 1, 2022, with earlier application permitted. The amendment is not currently applicable.

#### IAS 1 – "Presentation of Financial Statements"

The IASB issued an amendment to IAS 1, Presentation of Financial Statements to clarify one of the requirements under the standard for classifying a liability as non-current in nature, specifically the requirement for an entity to have the right to defer settlement of the liability for at least 12 months after the reporting period. The amendment includes: (i) specifying that an entity's right to defer settlement must exist at the end of the reporting period; (ii) clarifying that classification is unaffected by management's intentions or expectations about whether the entity will exercise its right to defer settlement; (iii) clarifying how lending conditions affect classification; and (iv) clarifying requirements for classifying liabilities an entity will or may settle by issuing its own equity instruments. An assessment will be performed prior to the effective date of January 1, 2023 to determine the impact to the Company's financial statements.



---

## Chemistree Technology Inc.

### Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

#### 4. PROPERTY AND EQUIPMENT

	Property \$	Equipment \$	Total \$
<b>COST</b>			
Balance, June 30, 2019	1,620,323	1,439,988	3,060,311
Additions	-	171,203	171,203
Balance, June 30, 2020	1,620,323	1,611,191	3,231,514
Additions	-	58,679	58,679
Reclassified to Asset held for sale / Net investment in sublease	(1,620,323)	(229,881)	(1,850,204)
<b>Balance, June 30, 2021</b>	-	1,439,989	1,439,989
<b>DEPRECIATION</b>			
Balance, June 30, 2019	-	276,323	276,323
Depreciation	-	124,243	124,243
Balance, June 30, 2020	-	400,566	400,566
Depreciation	-	105,413	105,413
Reclassifications	-	(8,559)	(8,559)
<b>Balance, June 30, 2021</b>	-	497,420	497,420
<b>NET BOOK VALUE</b>			
Balance, June 30, 2019	1,620,323	1,163,665	2,783,988
Balance, June 30, 2020	1,620,323	1,210,625	2,830,948
<b>Balance, June 30, 2021</b>	-	942,569	942,569

#### Washington Assets

Pursuant to a definitive asset purchase agreement (the "Washington Acquisition") between Chemistree Washington Ltd. ("Chemistree Washington") and Elite Holdings Inc. ("Elite"), on June 29, 2018 the Company acquired cultivation equipment for consideration of US\$1,000,000.

In addition to acquiring the Washington Assets, the Company entered into a Commercial Lease agreement effective July 1, 2018, with the landlord of the facility in which the Washington Assets are situated. The Commercial Lease agreement is for an initial term expiring on June 30, 2022, with an option to extend to June 30, 2026. Rent is payable to the landlord in the amount of USD \$10,025 per month (Note 12).

The Company sub-leases the Washington Assets to a Strategic Partner, as described in Note 12.

#### DHS Land

On August 7, 2018, through its wholly owned California subsidiary, CHM Desert LLC, the Company purchased 9.55 acres of vacant land in the city of Desert Hot Springs, Riverside County, California. Consideration for the purchase was USD \$1,233,800. The land is held for development purposes.

The property was disposed of subsequent to year end (Note 20). As a result, the property has been presented as an asset held for sale at year end with a corresponding liability held for sale representing a deposit to be applied against the purchase price.

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

**5. NOTES PAYABLE**

Effective July 17, 2017, the Company issued unsecured Promissory Notes (the “Notes”) to arm’s length parties, and a former related party, for borrowings from those parties. The Notes mature on July 17, 2027, and bear interest at the Canadian prime rate plus 0.5% per annum, payable annually.

	<b>Principal \$</b>
Balance, June 30, 2019	443,959
Additions	-
Balance, June 30, 2020	443,959
Additions	-
<b>Balance, June 30, 2021</b>	<b>443,959</b>

As at June 30, 2021, accrued and unpaid interest on these Notes amounts to \$65,537 (2020: \$52,377), which is presented as interest payable.

**6. RELATED PARTY TRANSACTIONS AND BALANCES**

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company’s Board of Directors and Officers.

During the years ended June 30, 2021 and 2020, the Company entered into transactions with key management personnel and related parties as follows:

Related party	Nature of transactions
Pacific Equity Management Corp. (“PEMC”)	Management fees for services provided by CEO, CFO, VP Corporate Development, VP Finance, Accountant, Secretary, Administrator and all support staff; includes rent and shared office expenses. Rent and shared office expenses commenced under a separate agreement on July 1, 2017.
Contact Financial Corp. (“CFC”)	Investor relations and communication services commenced under separate agreement on July 10, 2018.
Black Label (“BL”)	Expenses incurred by a company in which a Director is the principal shareholder.
Sheldon Aberman (“Aberman”), director	Fees for services provided by a Director. Investment in ACS, a company of which he is an officer (Note 16)
Nicholas Zitelli (“Zitelli”), director	Investment in ACS, a company of which he is an officer (Note 16)

The aggregate value of transactions involving key management personnel were as follows:

	<b>2021</b>	<b>2020</b>
Management fees <sup>(1)</sup>	\$ 600,000	\$ 720,000

<sup>(1)</sup> Until February 28, 2021, management fees were paid to PEMC, a company controlled by two officers of the Company for services provided by CEO, CFO, VP Corporate Development, Accountant, Secretary, Administrator and all support staff at the rate of \$60,000 per month. Effective March 1, 2021 the PEMC agreement was terminated by mutual consent; and under new agreements the CEO and President provides services at \$10,000 per month; the CFO/Secretary at \$10,000 per month; and the VP Corporate Development at \$10,000 per month. All of the March 1, 2021 agreements can be terminated by either party with six months’ notice.

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

The aggregate value of transactions with other related parties were as follows:

	<b>2021</b>	<b>2020</b>
Rent (general and administrative) <sup>(2)</sup>	\$ 30,000	\$ 30,000

<sup>(2)</sup> For the year ended June 30, 2021, rent was paid to PEMC for office rent and other office services. The Company is required to pay \$2,500 per month to PEMC (2020: \$2,500 per month). The agreement with PEMC can be terminated by either party with six months' notice.

The aggregate value of transactions with other related parties were as follows:

	<b>2021</b>	<b>2020</b>
Marketing (general and administrative) <sup>(3)</sup> (Note 15)	\$ 62,400	\$ 72,000

<sup>(3)</sup> For the year ended June 30, 2021, fees were paid to CFC for investor relations and communications services. The Company was required to pay \$6,000 per month until February 28, 2021. Effective March 1, 2021, the monthly amount was reduced to \$3600.

The aggregate value of transactions with other related parties were as follows:

	<b>2021</b>	<b>2020</b>
Management fees <sup>(4)</sup>	\$ 339,643	\$ 384,292

<sup>(4)</sup> For the year ended June 30, 2021, management fees were paid to Aberman. The Company was required to pay \$US 24,000 per month until February 28 2021. Effective March 1, 2021, the monthly amount was reduced to US\$18,000 per month for third party consulting services.

The aggregate value of transactions with other related parties were as follows:

	<b>2021</b>	<b>2020</b>
Share-based compensation	\$ -	\$ 46,000
Consulting <sup>(4)</sup>	\$ -	\$ 30,743
Equipment additions <sup>(4)</sup>	\$ 31,046	\$ 24,613
Investment <sup>(5)</sup> (Note 16)	\$ -	\$ 280,257
Travel <sup>(4)</sup>	\$ -	\$ 19,032

<sup>(4)</sup> For the year ended June 30, 2020, expenditures were paid to BL for various categories.

<sup>(5)</sup> Aberman and Zitelli were officers of ACS at the time of the investment.

Due to related parties include the following amounts:

	<b>2021</b>	<b>2020</b>
PEMC	\$ -	\$ 695

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

**7. SHARE CAPITAL AND EQUITY RESERVES**

a) Authorized: Unlimited common shares without par value

b) Issued common shares

*Year ended June 30, 2021*

The Company issued 720,000 common shares pursuant to the conversion of convertible debentures with a face value of \$360,000. Upon this conversion, \$335,598 was reclassified from convertible debentures and equity reserves to share capital. In addition, the Company issued 600,000 common shares pursuant to the exercise of stock options at \$0.06 per share.

*Year ended June 30, 2020:*

The Company issued 330,000 common shares pursuant to the conversion of convertible debentures. Upon this conversion, \$132,370 was reclassified from convertible debentures to share capital.

c) Warrants:

	<b>Warrants</b>	<b>Weighted Average Exercise Price \$</b>
Balance, June 30, 2019	35,897,955	0.62
Expired - unexercised	(7,409,323)	0.50
Balance, June 30, 2020	28,488,632	0.65
Expired - unexercised	(5,374,932)	0.50
<b>Balance, June 30, 2021</b>	<b>23,113,700</b>	<b>0.69</b>

As at June 30, 2021, the following warrants were outstanding and exercisable:

<b>Number</b>	<b>Exercise Price</b>	<b>Expiry Date</b>	<b>Remaining Contractual Life (in years)</b>
21,639,500	\$0.70	March 29, 2022	0.75
1,474,200	\$0.50	March 29, 2022	0.75

d) Options:

The Company has a Stock Option Plan (the "Plan") that allows it to give to eligible persons, as additional compensation, the opportunity to participate in the success of the Company by granting to such individuals stock options, exercisable over periods of up to five years, as determined by the board of directors of the Company, to buy shares of the Company at a price equal to the market price prevailing on the date the stock option is granted less applicable discount, if any, permitted by the policies of the Canadian Securities Exchange and approved by the Board. The maximum number of Shares which may be issuable pursuant to options granted under the Plan shall be that number equal to 10% of the Company's issued share capital from time to time.

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

	Options	Weighted Average Exercise Price \$
Balance, June 30, 2019	2,650,000	0.40
Granted	1,450,000	0.06
Terminated	(400,000)	0.34
Balance, June 30, 2020	3,700,000	0.27
Exercised	(600,000)	0.06
Expired	(50,000)	0.36
<b>Balance, June 30, 2021</b>	<b>3,050,000</b>	<b>0.31</b>

As at June 30, 2021, the following stock options were outstanding and exercisable:

Number	Exercise Price	Expiry Date	Remaining Contractual Life (in years)
750,000	\$0.10	June 7, 2022	0.94
250,000	\$0.41	July 11, 2023	2.03
1,200,000	\$0.60	April 5, 2024	2.77
850,000	\$0.06	April 9, 2025	3.78

These options entitle the holder thereof the right to acquire one common share for each option held. The weighted average remaining life of the outstanding stock options is 2.54 years.

During the year ended June 30, 2021, the Company granted nil stock options to acquire nil (2020: 1,450,000) common shares with a fair value of \$nil (2020: \$58,000). The options granted during the period vested on the grant date. The fair value of each option was estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:

	2021	2020
Risk-free interest rate	-	0.59%
Expected life	-	5 years
Expected volatility	-	145.62%
Expected dividend yield	-	Nil
Weighted average fair value	-	\$0.04

## 8. CONVERTIBLE DEBENTURE

On March 29, 2019, the Company completed a short form prospectus offering in each of the provinces of Canada, other than Québec (the “Brokered Offering”) and a concurrent private placement (the “Concurrent Private Placement”) of 10% unsecured debenture units (the “Debenture Units”) of the Company, for total gross proceeds of \$10,830,000.

Pursuant to the Brokered Offering, which included the exercise of the over-allotment option in full, the Company issued an aggregate of 9,430 Debenture Units at a price of \$1,000 per Debenture Unit (the “Offering Price”) for aggregate gross proceeds of \$9,430,000. Each Debenture Unit consists of (i) one 10% unsecured convertible debenture of the Company in the principal amount of \$1,000 (each, a “Debenture”)

---

## Chemistree Technology Inc.

### Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

with interest payable semi-annually in arrears on June 30 and December 31 of each year, commencing June 30, 2019 and maturing March 29, 2022 (such date, the “Maturity Date”), and (ii) 2,000 common share purchase warrants of the Company (each, a “Warrant”), each exercisable until the Maturity Date to purchase one common share of the Company (each, a “Warrant Share”) at an exercise price of \$0.70 per Warrant Share, subject to adjustment in certain events.

Concurrent with the Brokered Offering, the Company issued an aggregate of 1,400 Debenture Units at the Offering Price, for aggregate gross proceeds of \$1,400,000, on a private placement basis.

Each Debenture is convertible at the option of the holder of the Debenture (each, a “Debentureholder”) into common shares in the capital of the Company (the “Debenture Shares”) at any time prior to the earlier of (i) the last business day immediately preceding the Maturity Date, subject to Mandatory Conversion as defined in the Debenture Indenture, and (ii) the business day immediately preceding the date specified for redemption of the Debentures upon a Change of Control as defined in the Debenture Indenture, at a conversion price of \$0.50 per Debenture Share, subject to adjustment in certain events (the “Conversion Price”). Upon conversion, Debentureholders will receive accrued and unpaid interest thereon for the period from and including the date of the latest interest payment date to and including the date of conversion.

In connection with the Brokered Offering, the Company: (i) paid the Agent a cash commission equal to 7.0% of the gross proceeds of the Offering; (ii) paid the Agent a corporate finance fee of \$156,000, of which \$75,000 was paid in cash and \$81,000 was satisfied through the issuance of 150,000 Common Shares; (iii) issued the Agent non-transferable broker warrants (the “Broker Warrants”) to purchase 1,320,200 units of the Company (the “Broker Units”) at an exercise price of \$0.50 per Broker Unit; and (iv) paid the Agent a fiscal advisory fee comprised of \$14,000 in cash and the issuance of 14,000 Broker Warrants.

Each Broker Unit consists of one common share of the Company (each, a “Broker Unit Share”) and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Broker Unit Warrant”). Each Broker Unit Warrant will be exercisable to acquire one common share of the Company (each, a “Broker Warrant Share”) at any time up until the Maturity Date at an exercise price of \$0.70 per Broker Warrant Share, subject to adjustment in certain events.

In connection with the Concurrent Private Placement, the Company: (i) paid certain finders (each, a “Finder”) a cash commission equal to 7.0% of the gross proceeds; and (ii) issued to such Finders an aggregate of 140,000 Broker Warrants.

The Company recorded issuance costs of \$2,027,206 associated with the professional fees and financing costs incurred. The net proceeds were allocated first to the fair value of the convertible note, with the remaining \$790,394 and \$292,322 allocated to the equity component and deferred income tax liability, respectively. The fair value was determined by using an interest rate approximating the Company’s market rate of interest for a similar debt instrument. The liability component of the debt is accreted to its face value over the term of the convertible debenture.

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

	Liability Component		Deferred income tax liability Component	Equity Component
	Face Value	Carrying Value		
Balance as at June 30, 2019	\$9,732,000	\$7,096,455	\$ -	\$710,260
converted	(165,000)	(122,882)	(4,454)	(9,488)
accretion	-	766,197	-	-
recovered	-	-	4,454	-
Balance as at June 30, 2020	\$9,567,000	\$7,739,770	\$ -	\$700,772
converted	(360,000)	(306,772)	-	(28,828)
accretion	-	937,711	-	-
recovered	-	-	-	-
<b>Balance as at June 30, 2021</b>	<b>\$ 9,207,000</b>	<b>\$ 8,370,709</b>	<b>\$ -</b>	<b>\$ 671,944</b>

Details of the convertible debenture classification are as follows:

	June 30, 2021
Proceeds from the issue of convertible debentures	\$ 10,830,000
Transaction costs	(2,027,206)
Equity component	(790,394)
Deferred income tax liability	(292,322)
Conversions	(1,218,011)
Accretion	1,868,642
Ending balance	<b>\$ 8,370,709</b>
Current portion	<b>8,370,709</b>
<b>Non-current portion</b>	<b>\$ -</b>

During the year ended June 30, 2021, the Company incurred \$937,286 (paid) (2020 - \$960,168) in interest expense on the Convertible Debentures.

## 9. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to pursue and complete the identification and evaluation of assets, properties or businesses with a view to acquisition or participation in a qualifying transaction, to maintain financial strength and to protect its ability to meet its on-going liabilities, to continue as a going concern, to maintain credit worthiness and to maximize returns for shareholders over the long term. The Company does not have any externally imposed capital requirements to which it is subject. Capital is comprised of the Company's shareholders' equity. There were no changes made to the Company's capital management approach during the years presented.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares or adjust the amount of cash and cash equivalents.

The Company's investment policy is to invest its cash in investment instruments in high credit quality financial institutions with terms to maturity selected with regards to the expected time of expenditures from continuing operations.

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

### 10. FINANCIAL INSTRUMENTS, FAIR VALUE MEASUREMENT AND RISK

#### a) Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, receivables, note receivable, investment, accounts payable and accrued liabilities, due to related parties, interest payable, notes payable, and convertible debenture.

#### b) Fair Value Measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy establishes three levels to classify the inputs to valuation techniques used to measure fair value, by reference to the reliability of the inputs used to estimate the fair values, as follows:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value of cash and cash equivalents are determined based on Level 1 inputs which consist of quoted prices in active markets for identical assets. The carrying values of receivables, note receivable, accounts payable and accrued liabilities, due to related parties, interest payable, notes payable, and convertible debenture all approximate their fair values.

The fair value of the Investment is determined based on Level 3 inputs, described in Note 16.

#### c) Financial Risks

##### (i) Credit Risk

Credit risk arises from the non-performance by counterparties of contractual financial obligations. The Company's maximum exposure to credit risk is \$499,971, consisting of cash and cash equivalents, receivables and taxes receivable. The Company limits its exposure to credit loss for cash and cash equivalents by placing such instruments with high credit quality financial institutions. The values of these instruments may exceed amounts insured by an agency of the Government of Canada. In management's opinion, the Company's credit risk related to these instruments, is low. See Note 17 with regards to credit risk of receivables.

##### (ii) Liquidity Risk

The Company's approach to managing liquidity risk is to ensure that it will have sufficient financial resources to meet liabilities when due. As at June 30, 2021, the Company had a working capital deficit of \$6,342,110. Except for notes payable and convertible debentures, all of the Company's financial liabilities have contractual maturities of less than 30 days and are subject to normal trade terms. As at June 30, 2021, the Company has insufficient working capital to discharge its existing financial obligations, refer to Note 1 for detail regarding going concern.

##### (iii) Interest Rate Risk

The Company is subject to interest rate risk as its cash and cash equivalents, notes payable bear interest at variable rates; and its convertible debentures at a fixed rate. The impact of a 1% change in interest rates would have an insignificant impact on the Company's profit or loss.

##### (iv) Foreign Currency Risk

Currency risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate



---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

because of changes in foreign exchange rates. Amounts subject to currency risk are primarily cash and cash equivalents, accounts receivable, and accounts payable and accrued liabilities denominated in United States dollars. A 10% change in foreign exchange rates is expected to have a US\$ 6,000 impact on the Company's profit or loss.

(v) Price Risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. As at June 30, 2021 the Company is exposed to this risk with respect to its Investments. A 10% increase/decrease in the price of Investments would impact net loss by approximately \$50,000.

### 11. SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS

During the year ended June 30, 2021, the Company:

- Reclassified \$306,772 into share capital from convertible debentures and equity reserves upon conversion of debentures (Note 8).
- Recognized Investment in sublease in the amount of \$221,322 (Note 12), resulting in a non-cash gain of \$102,598.

During the year ended June 30, 2020, the Company:

- Reclassified the loan receivable to trade and other receivable in the amount of \$523,415.
- Reclassified \$122,882 into share capital from convertible debentures, deferred income tax liability, and equity reserves upon conversion of debentures (Note 8).
- Recognized a 'Right-of-use'/Lease Liability in the amount of \$407,334 (Note 12).
- Derecognized Right-of-use asset, and recognized Investment in sublease in the amount of \$411,981 (Note 12), resulting in a non-cash gain of \$4,647 with other income.

### 12. LEASES

#### Investment in sublease

On July 1, 2020, the Company adopted IFRS 16, Leases. As a result, the Company recognized an investment in sublease on July 1, 2020 for its sub-lease of a facility in Washington described in Note 4, which was determined to meet classification as a finance lease. Set out below, are the carrying amounts of the Company's investment in sublease and the movements during the year:

	<b>Investment in Sublease</b>
	\$
Lease payments as at June 30, 2019	471,987
Incremental borrowing rate as at July 1, 2019	10%
Discounted operating lease payments as at July 1, 2019	411,981
Interest accretion	35,227
Lease payments received	(161,035)
Foreign exchange	13,037
As at June 30, 2020	299,210
Initial Direct Costs of Lease Amendment	221,322
Adjustment for increased sublease payments	102,598
Finance income	41,824
Lease payments received or accrued	(320,898)

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

Impairment	(148,161)
Foreign exchange	(47,433)
As at June 30, 2021	148,462
Current portion of investment sublease	148,462
Long-term portion of investment in sublease	-

On July 1, 2020, there was an increase in the sublease payment of USD10,850 per month for improvements on the assets being leased. The improvements, part of which were in property and equipment at year end and part of which were additions during the period, when recorded at estimated discounted cash flows resulted in a gain on sublease of \$102,598. At June 30, 2021, the Company reviewed the credit quality of the investment in sub-lease and recorded an impairment of \$148,161 based on historical collection rates.

### Right-of-use assets and lease liabilities

On January 1, 2019, the Company adopted IFRS 16, Leases. The new standard brings most leases on-balance sheet for lessees under a single model, eliminating the distinction between operating and finance leases. Under the new standard, a lessee recognizes a right-of-use asset and a lease liability. The right-of-use asset is treated similarly to other non-financial assets and depreciated accordingly. The Company has a Commercial Lease described in Note 4.

The Company has recorded these leases as a right-of-use assets and lease liability in the statement of financial position as at June 30, 2020. On July 1, 2019, the lease liability was measured at the present value of the future lease payments that were not paid at that date. These lease payments are discounted using a discount rate of 10%, which is the Company's incremental borrowing rate.

Set out below, are the carrying amounts of the Company's right-of-use assets and lease liabilities and movements during the period:

	Right-of-use Assets \$	Lease Liabilities \$
Operating lease commitments as at June 30, 2019	-	473,167
Incremental borrowing rate as at July 1, 2019	-	10%
Discounted operating lease commitments as at July 1, 2019	407,334	407,334
Investment in sublease	(407,334)	-
Interest accretion	-	37,242
Lease payments	-	(162,414)
Foreign exchange	-	13,205
As at June 30, 2020		295,367
Interest accretion	-	22,017
Lease payments	-	(154,293)
Foreign exchange	-	(21,752)
As at June 30, 2021	-	141,339
Current portion of lease liability	-	141,339
Long-term portion of lease liability	-	-

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

The Company's minimum undiscounted contractual lease payments are as follows:

---

Less than 1 year	USD120,300
1 to 2 years	Nil
2 to 5 years	Nil

---

### 13. SEGMENTED INFORMATION

The Company operates in one reportable segment, being the business investing in the United States cannabis sector. As at June 30, 2021 and 2020, with the exception of one investment (Note 16) held in Canada, all the Company's non-current assets were located in the United States.

### 14. NOTE RECEIVABLE

a) Arcata Loan

In November 2018, the Company entered into a strategic collaboration ("Arcata") with a Humboldt County-based cannabis processing company ("Processor") located in Arcata, California. Pursuant to the Collaboration Agreement, the Company agreed to loan the Processor US\$450,000 (the "Arcata Loan") by way of a secured note (hereafter, "Note"), for the purposes of the expanding the Processor's business, including to, among other things, purchase additional equipment and complete tenant improvements to the Processor's facility. The Note is secured by 50% of the equity of the Processor, bore interest at 6% per annum and matured on March 14, 2020. The Note is in default, the Processor has refused to retire the principal and interest and has blocked the Company from realizing on its security. As such and in accordance with the uncertain of collectability of the Note, in the year ended June 30, 2020, the Company recorded an impairment expense of \$685,429 to reduce the carrying value of the receivable to \$1, included within Receivables on the consolidated statement of financial position.

---

	Note Receivable \$
Balance, June 30, 2019	610,061
Accrued interest	25,311
FX translation	50,058
Impairment	(685,429)
<b>Balance, June 30, 2021 and 2020</b>	<b>1</b>

---

b) Promissory Note

On July 26, 2019, the Company loaned US\$351,000 to an arms' length borrower (the "Borrower") pursuant to a letter agreement and Promissory Note. The note is due on demand and bears interest at 10% per annum. The note is secured by a pledge of a separate loan agreement between the Borrower and Umbrella Industries USA, LLC dated as of April 11, 2019. Effective May 1, 2021 the Company extended the Note's maturity for one-year and has been granted asset-backed security for the debt obligation. As such and in accordance with the uncertain of collectability of the Note, in the year ended June 30, 2021, the Company recorded an impairment expense of \$514,478 to reduce the carrying value of the receivable to \$nil.

---

# Chemistree Technology Inc.

## Notes to the Consolidated Financial Statements

For the years ended June 30, 2021 and 2020

(in Canadian dollars)

---

### 15. COMMITMENTS

Effective July 10, 2018, the Company entered into a consulting agreement with Contact Financial Corp. ("CFC") to provide investor relations and communication services.

As at June 30, 2021, the Company's commitments are as follows:

- CFC: \$3,600 per month for consulting
- CEO and President \$10,000 per month for management services
- CFO and Secretary \$10,000 per month for management services
- VP Corporate Development \$10,000 per month for management services
- Accountant \$5,500 per month for accounting services
- PEMC \$2,500 per month for rent and office services
- CCO US\$18,000 for management services

Minimum commitments related to leases within the scope of IFRS 16 are disclosed in Note 12.

### 16. INVESTMENTS

- a) During the year ended June 30, 2021, the Company completed the first tranche of the investment into ImmuoFlex Therapeutics Inc. ("ImmunoFlex"). The definitive investment agreement includes Chemistree's initial common share purchase of \$500,000, together with Chemistree being granted a gross sales royalty on ImmunoFlex's North American sales. A further \$500,000 second tranche common share purchase is conditional on certain performance by ImmunoFlex or at the election of Chemistree. In addition, ImmunoFlex has now appointed Chemistree's Chief Financial Officer to ImmunoFlex's board of directors. Chemistree is also entitled to anti-dilution pre-emptive rights regarding its share ownership. ImmunoFlex's products are targeted at prevention and treatment of viruses and improving vaccine effectiveness by safely improving immunity biomarkers and enhancing the immune system as it actively responds to disease.
- b) During the previous year, the Company completed the acquisition of an interest in Applied Cannabis Sciences of New Jersey ("ACS"), a private company and New Jersey-based applicant for a medical, vertically integrated cannabis license. The investment is a 10% Preferred Membership Interest in ACS, a New Jersey limited liability company and is represented by ownership of ten Class A shares of ACS. The consideration for the investment was \$US 215,000 (equivalent to \$CAD 280,257). Concurrent with the investment, Chemistree's Chief Financial Officer was appointed CFO of ACS.

To date, there has been no valuation of ACS or its equity completed and no financial information made available. Management has determined to impair this investment as it has not changed since its initial acquisition because the application for the above-mentioned licenses in New Jersey remain in the processing queue. Absent any other information being available, the Investments fair value at June 30, 2021, is deemed to be \$nil.

---

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

---

## 17. RECEIVABLES

Receivables consist of the consulting fees, rental charges and advances towards improvements of the Washington Assets. As at June 30, 2021, the Company has assessed a deterioration of credit quality and applied the expected credit loss model under the guidance of IFRS 9, as follows:

- Current: 0% of carrying value
- Less than 12 months past due: 50% of carrying value
- More than 12 months past due: 100% of carrying value

As a result of applying the above model, the Company has taken allowances for \$199,231 (2020 - \$689,125) in receivables, recognized as bad debt expense in profit and loss.

## 18. COVID-19 PANDEMIC

During the previous year and ongoing in the current year, the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

## 19. INCOME TAXES

A reconciliation of income taxes at statutory rates with the reported taxes is as follows:

	2021	2020
Loss for the year	\$ (4,533,978)	(5,453,452)
Computed income taxes (recovery)	\$ (1,224,000)	(1,472,000)
Change in statutory rate	72,000	73,000
Permanent differences	44,000	31,000
Adjustment to prior years provision versus statutory tax returns	330,000	-
Change in unrecognized deductible temporary	778,000	1,368,000
<b>Total income tax expense (recovery)</b>	<b>\$ -</b>	<b>-</b>
<b>Current income tax</b>	<b>-</b>	<b>-</b>
<b>Deferred tax recovery</b>	<b>-</b>	<b>-</b>

---

**Chemistree Technology Inc.**  
**Notes to the Consolidated Financial Statements**  
For the years ended June 30, 2021 and 2020  
(in Canadian dollars)

The significant components of the Company's deferred tax assets that have not been included on the consolidated statement of financial position are as follows:

	2021	2020
Deferred tax assets (liabilities)		
Exploration and evaluation assets	\$ 758,000	758,000
Property and equipment	(187,000)	(219,000)
Share issue costs	169,000	258,000
Investment	59,000	-
Debt with accretion	(226,000)	(493,000)
Note receivable	108,000	-
Allowable capital losses	-	4,000
Non-capital losses available for future period	4,154,000	3,749,000
	\$ 4,835,000	4,057,000
Unrecognized deferred tax assets	(4,835,000)	(4,057,000)
<b>Net deferred tax assets</b>	<b>-</b>	<b>-</b>

The significant components of the Company's temporary differences, unused tax credits and unused tax losses that have not been included on the consolidated statement of financial position are as follows:

	2021	Expiry Date Range	2020	Expiry Date Range
<b>Temporary Differences</b>				
Exploration and evaluation assets	\$ 2,809,000	No expiry date	\$ 2,809,000	No expiry date
Share issue costs	624,000	2042 to 2043	955,000	2041 to 2043
Investment	280,000	No expiry date	-	No expiry date
Note receivable	514,000	No expiry date	-	No expiry date
Allowable capital losses	-	No expiry date	16,000	No expiry date
Non-capital losses available for future periods	14,120,000		11,754,000	
Canada	12,930,000	2029 to 2041	9,466,000	2029 to 2040
USA	\$ 1,190,000	No expiry date	\$ 2,288,000	No expiry date

Tax attributes are subject to review, and potential adjustment, by tax authorities.

## 20. EVENTS AFTER THE REPORTING PERIOD

- a) 1,318 convertible debentures, representing \$1,318,000 in debt obligation of the Company were converted into 2,636,000 common shares.
- b) On July 22, 2021, the Company completed the sale of the DHS Land (Note 4) for gross proceeds of US\$1,957,000. In conjunction with the sale, the Company negotiated a back-in option agreement with the purchaser, such that as the purchaser advances the construction of the project, renamed AMP Industrial Park, the Company has the unilateral option to acquire a new 16,460-square-foot cannabis production and processing building at a predetermined price.